ATLANTA, GA--(Marketwired - Oct 3, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that its Senior Vice President of Research and Development, Dr. Farshad Guirakhoo, will present at three upcoming scientific conferences.
At the 2016 International Society for Vaccines Annual Congress, being held in Boston, MA on October 2-4, Dr. Guirakhoo's oral presentation is entitled "Unitizing MVA-VLP Platform for Development of Single Dose Vaccines: Tetravalent Vaccine Against Hemorrhagic Fever and Zika Viruses."
At the International Meeting on Emerging Diseases and Surveillance (IMED), to be held in Vienna, Austria on November 4-7, Dr. Guirakhoo's oral presentation is entitled, "Development of a Zika Vaccine Using a Novel MVA-VLP Platform."
At Vaccines R&D 2016, to be held in Cartagena, Colombia on November 10-12, Dr. Guirakhoo will give two talks, entitled "Development of a Tetravalent Vaccine for Ebola, Sudan, Marburg, and Lassa Viruses" and "Development of a Vaccine for Zika."
Both Ebola and Zika viruses have been known for many years; yet, in recent epidemics, their emergence has caught public health officials off-guard, with no vaccines or drugs available to stem their global spread. Dr. Guirakhoo's presentations will focus on GeoVax's vaccine development efforts using its 4th generation Modified Vaccinia Virus Ankara (MVA) Virus-like Particle (VLP) technology, improved for transgene stability and designed to produce VLPs in the vaccinated individual. GeoVax's MVA-VLP platform has been validated in non-human primates (NHP) for Ebola, as well as in five human clinical trials for its HIV vaccine.
GeoVax's tetravalent vaccine against hemorrhagic fever viruses is composed of four recombinant MVA vectors that express VLPs displaying the native glycoproteins of the four target viruses (Ebola, Sudan, Marburg and Lassa). Initial proof of concept studies demonstrated 100% protection against a lethal dose of the Ebola virus in guinea pigs, Syrian golden hamsters, and NHPs (as a single dose or 2 dose regimen). This is the first report that a replication deficient MVA vector can confer full protection of NHP against Ebola after a single dose vaccination. The Company's next step is to test its full tetravalent vaccine in NHPs before proceeding to human phase 1 clinical testing.
For the Company's Zika vaccine, two MVA-VLP vaccine candidates are being developed from the Suriname 2015 strain of Zika virus. Animal efficacy experiments using two different mouse models developed at the Centers for Disease Control and Prevention (CDC) and the University of Georgia are currently ongoing.
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. The Company's development programs are focused on vaccines against HIV, Zika Virus, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa). GeoVax also recently began programs to evaluate the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious virus-like particles (VLPs) from the cells of the very person receiving the vaccine, mimicking a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.